Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan 80mg Non-responder Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Essential hypertensive patients~  * If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be \>=90 and \>=114 mmHg~ * If not taking any antihypertensive drugs, mean seated DBP must be \>=95 and \>=114 mmHg~* Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.~Exclusion criteria:~* Patients taking 3 or more antihypertensive drugs at signing the informed consent form~* Patients with known or suspected secondary hypertension~* Patients with clinically relevant cardiac arrhythmia~* Congestive heart failure with New York Heart Association (NYHA) functional class III-IV~* Patients with recent cardiovascular events~* Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form~* Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy~* Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors~* Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs~* Patients with hepatic and/or renal dysfunction~* Pre-menopausal women who are nursing or pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan and amlodipine FDC (Type: EXPERIMENTAL): once a daily
- Telmisartan monotherapy (Type: ACTIVE_COMPARATOR): once a daily

Based on this trial design, predict the completion outcome and termination type (if applicable).